Corvus Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Corvus Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • Corvus Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $83M, a 8.71% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $83M +$6.65M +8.71% Dec 31, 2023 10-K 2024-03-19
Q4 2022 $76.3M +$9.2M +13.7% Dec 31, 2022 10-K 2024-03-19
Q4 2021 $67.1M +$11.4M +20.6% Dec 31, 2021 10-K 2024-03-19
Q4 2020 $55.7M +$1.46M +2.69% Dec 31, 2020 10-K 2023-03-28
Q4 2019 $54.2M +$13M +31.5% Dec 31, 2019 10-K 2022-03-10
Q4 2018 $41.2M +$19.4M +88.4% Dec 31, 2018 10-K 2021-03-25
Q4 2017 $21.9M +$9.09M +71.1% Dec 31, 2017 10-K 2020-03-09
Q4 2016 $12.8M +$6.93M +118% Dec 31, 2016 10-K 2019-03-07
Q4 2015 $5.87M Dec 31, 2015 10-K 2018-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.